A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Patients with recurrent UTI were randomized to receive either the probiotic Sacchromyces
Boulardii at enrollment, and the intracellularly active Ciprofloxacin with their first UTI
episode after enrollment, or they received standard of care treatment.
Phase:
Early Phase 1
Details
Lead Sponsor:
Ann & Robert H Lurie Children's Hospital of Chicago